Rabeprazole and Enophthalmos - a phase IV clinical study of FDA data

Summary:

Enophthalmos is reported as a side effect among people who take Rabeprazole (rabeprazole sodium), especially for people who are female, 60+ old, also take Amlodipine, and have Disorder of orbit.

The phase IV clinical study analyzes which people have Enophthalmos when taking Rabeprazole. It is created by eHealthMe based on reports of 31,196 people who have side effects when taking Rabeprazole from the FDA, and is updated regularly.

What is Rabeprazole?

Rabeprazole has active ingredients of rabeprazole sodium. It is often used in gastroesophageal reflux disease. eHealthMe is studying from 31,689 Rabeprazole users. Check the latest studies of Rabeprazole.

What is Enophthalmos?

Enophthalmos (posterior displacement of the eye) is found to be associated with 23 drugs and 67 conditions by eHealthMe. Check the latest studies of Enophthalmos.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 25, 2026

31,196 people reported to have side effects when taking Rabeprazole.
Among them, 12 people (0.04%) have Enophthalmos.

Among these 12 people:

What is the gender of people who have Enophthalmos when taking Rabeprazole? *

female: 100 %
male: 0.0 %

What is the age of people who have Enophthalmos when taking Rabeprazole? *

What are other drugs people take besides Rabeprazole? *

What are other side effects people have besides Enophthalmos? *

Weight Increased: 12 people, 100.00%
Peripheral Swelling: 12 people, 100.00%
Neutrophil Count Decreased (less than normal number of neutrophil a type of blood cell): 12 people, 100.00%
Infusion Related Reaction: 12 people, 100.00%
Headache (pain in head): 12 people, 100.00%
Dyspnea (difficult or laboured breathing): 12 people, 100.00%
Dry Mouth: 12 people, 100.00%
Blood Pressure Systolic Increased: 12 people, 100.00%
Blood Pressure Systolic Abnormal: 12 people, 100.00%
Blood Pressure Diastolic Abnormal: 12 people, 100.00%

What are the existing conditions these people have? *

Disorder Of Orbit: 12 people, 100.00%

* Approximation only. Some reports may have incomplete information.

Do you take Rabeprazole and have Enophthalmos?

- Check whether Enophthalmos is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Rabeprazole:

Rabeprazole (31,689 reports)

Enophthalmos treatments and more:

Enophthalmos (130 reports)

Browse all side effects of Rabeprazole:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Enophthalmos:

Enophthalmos (23 drugs)

Browse all the conditions that are associated with Enophthalmos:

Enophthalmos (67 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on rabeprazole sodium (the active ingredients of Rabeprazole) and Rabeprazole (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.